Skip to main content
SpringerLink
Log in

Candesartan (Blopress, Atacand)

Antihypertensive Drug with a New Mechanism of Action

  • Chapter
  • First Online:
Drug Discovery in Japan

  • 691 Accesses

Abstract

Candesartan (Blopress) is an antihypertensive drug known to act as an angiotensin-II receptor blocker (ARB). It was discovered and developed by Takeda Pharmaceutical . Compared to earlier antihypertensive drugs, candesartan had a new mechanism of action , fewer side effects , and demonstrated efficacy even at low doses. The research project started as exploratory research on diuretics. Takeda discovered CV-2198, the first nonpeptidic ARB, by making full use of spontaneously hypertensive rats (a pathological animal model) provided by academia, and through capturing serendipitous event brought about by cutting-edge chemical synthesis methodology. However, the project was suspended because of weak efficacy, while DuPont developed losartan, building on the Takeda’s invention. Although preceded by DuPont, Takeda quickly responded, and successfully launched candesartan shortly after. The case of candesartan is a good illustration of the role of unique capabilities and the overall organizational strength for innovative drug discovery, as well as the difficulty of go/no-go decisions and indicates the importance of flexible allocation of resources for grasping opportunities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abe, K., & Tsunoda, K. (2002). Kidney domain 100 years: renal hypertension. Journal of the Japanese Society of Internal Medicine, 91(5), 1393–1400.

    Article  Google Scholar 

  • Arakawa, K. (2006). Looking back on renin-angiotensin system research in Japan (from ACE inhibitors to ARBs). Horiuchi, M. (Ed.), THE ARB. Medical Reviews, pp. 3–11.

    Google Scholar 

  • Arakawa, K., Nakatani, M., Minohara, A., & Nakamura, M. (1967). Isolation and amino acid composition of human angiotensin I. Biochemical Journal, 104, 900–906.

    Article  Google Scholar 

  • Bhardwaj, G. (2006). How the antihypertensive losartan was discovered. Expert Opinion on Drug Discovery, 1(6), 609–18.

    Article  Google Scholar 

  • Bumpus, F. M., Schwarz, H., & Page, I. H. (1957). Synthesis and pharmacology of the octapeptide angiotonin. Science, 125(3253), 886–887.

    Article  Google Scholar 

  • Fukamizu, A. (2011). Chapter 5: The life sciences of mysteries-from accidental discoveries. The Life Sciences-Image of Tsukuba Researchers. http://www.science-academy.jp/rensai/pdf/rensai_5.pdf. Accessed in February 20, 2014.

  • Goldblatt, H., Lynch, J., Hanzal, R. F., & Summerville, W. W. (1934). Studies on experimental hypertension I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. The Journal of experimental medicine, 59(3), 347–379.

    Google Scholar 

  • Gross, F. (1958). Renin und Hypertensin, physiologische oder pathologische Wirkstoffe? Klinische Wochenschrift, 36(15), 693–706.

    Article  Google Scholar 

  • Imai, T., Miyazaki, H., Hirose, S., Hori, H., Hayashi, T., Kageyama, R., et al. (1983). Cloning and sequence analysis of cDNA for human renin precursor. Proceedings of the National Academy of Sciences, 80(24), 7405–7409.

    Article  Google Scholar 

  • Imura, Y. (2010). SHR and drug discovery research. News Letter of the Joint Society for Models of Diseases, including SHR, 35, 1–2.

    Google Scholar 

  • Inada, Y., & Naka, T. (2000). Pharmacological properties and organ protective effects of a new generation of angiotensin-II receptor antagonists of candesartan cilexetil. Journal of Science, Japanese Drug, 115(3), 151–160.

    Google Scholar 

  • Kagami, S. (2010). History of the Renin-Angiotensin System (RAS): From bench to bed: Why basic studies are important for clinicians. Japanese Journal of Nephrology, 23(2), 179–182.

    Google Scholar 

  • Kambayashi, Y., Bardhan, S., Takahashi, K., Tsuzuki, S., Inui, H., Hamakubo, T., et al. (1993). Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. Journal of Biological Chemistry, 268(33), 24543–24546.

    Google Scholar 

  • Khairallah, P. A., Toth, A., & Bumpus, F. M. (1970). Analogs of angiotensin II. II. Mechanism of receptor interaction. Journal of medicinal chemistry, 13(2), 181–184.

    Google Scholar 

  • Kokubu, T., Ueda, E., Fujimoto, S., Hiwada, K., Kato, A., Akutsu, H., et al. (1968). Peptide inhibitors of the renin–angiotensin system. Nature, 217, 456–457.

    Article  Google Scholar 

  • Kubo, K. (2006). Creation of the antihypertensive drug candesartan cilexetil. Chem & Education, 54(3), 138–141.

    Google Scholar 

  • Kubo, K., Kohara, Y., Yoshimura, Y., Inada, Y., Shibouta, Y., Furukawa, Y., et al. (1993). Nonpeptide angiotensin II receptor antagonists: Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. Journal of Medicinal Chemistry, 36(16), 2343–2349.

    Article  Google Scholar 

  • Kuno, Y., & Sato, K. (2011). How is a drug discovery science introduction made? Ohm.

    Google Scholar 

  • Marks, L. S., & Maxwell, M. H. (1979). Tigerstedt and the discovery of renin: An historical note. Hypertension, 1(4), 384–388.

    Article  Google Scholar 

  • Morita, K. (2000). New drugs are developed in this way: A development secret by the president of the researcher. Nihon Keizai Shimbunsya.

    Google Scholar 

  • Morrison, A. R., Nishikawa, K., & Needleman, P. (1977). Unmasking of thromboxane A2 synthesis by ureteral obstruction in the rabbit kidney. Nature, 267, 259–260.

    Article  Google Scholar 

  • Nagaoka, A. (1987). Application to drug development in spontaneously hypertensive rats (SHR). Record of the Japanese Society of Model Animal Animals, 3, 30–35.

    Google Scholar 

  • Naka, T. (2001). Angiotensin II receptor antagonist: candesartan cilexetil (Blopress) (a drug developed in Japan). Journal of Specialist Physicians of the Japanese Society of Cardiology, 9(2), 313–318.

    Google Scholar 

  • Naka, T., Kubo, K., & Furukawa, Y. (1995). Research and development of non-peptide angiotensin II receptor antagonists. Journal of the Society of Synthetic Organic Chemistry, 53(9), 802–810.

    Article  Google Scholar 

  • Nikkei Business. (1997). New drugs with fewer side effects that suppress the action of vasoconstrictors in the treatment of hypertension. Issue December 8, pp. 61–64.

    Google Scholar 

  • Nishikawa, K. (2007). Development of ARBs [Basic Edition]—Finding lead compounds from research on diuretics. Blood Pressure, 14(5), 71–83.

    Google Scholar 

  • Ogihara, T., & Kumahara, Y. (1982). Renin-angiotensin system inhibitor. Medicina, 19(11), 1998–1999.

    Google Scholar 

  • Page, I. H. (1990). Hypertension research. A memoir 1920–1960. Hypertension, 16(2), 199–200.

    Article  Google Scholar 

  • Shimamoto, K. (2011). Obesity and hypertension. Journal of the Japanese Society of Internal Medicine, 100(4), 945–949.

    Article  Google Scholar 

  • Skeggs, L. T., Marsh, W. H., Kahn, J. R., & Shumway, N. P. (1954). The existence of two forms of hypertensin. The Journal of Experimental Medicine, 99(3), 275–282.

    Article  Google Scholar 

  • Skeggs, L. T., Kahn, J. R., & Shumway, N. P. (1956). The preparation and function of the hypertensin-converting enzyme. The Journal of Experimental Medicine, 103(3), 295–299.

    Article  Google Scholar 

  • Yanagisawa, H. (2006). History of renin-angiotensin system inhibitors angiotensin receptor antagonist. In Horiuchi, M. (Ed.), THE ARB. Medical Reviews, pp. 252–264.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Advanced Sciences, Yokohama National University, Kanagawa, Japan

    Naoki Takada

  2. Career Development Department, Shionogi Career Development Center Co., Ltd, Osaka, Japan

    Koichi Genda

  3. Medical Affairs, Medical Science Liaison, MSD K.K., Tokyo, Japan

    Akira Nagumo

Authors
  1. Naoki Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koichi Genda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Nagumo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoki Takada .

Editor information

Editors and Affiliations

  1. Department of Economics, Tokyo Keizai University, Kokubunji, Tokyo, Japan

    Sadao Nagaoka

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Takada, N., Genda, K., Nagumo, A. (2019). Candesartan (Blopress, Atacand). In: Nagaoka, S. (eds) Drug Discovery in Japan. Springer, Singapore. https://doi.org/10.1007/978-981-13-8906-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-8906-1_12

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-8905-4

  • Online ISBN: 978-981-13-8906-1

  • eBook Packages: Economics and FinanceEconomics and Finance (R0)

Publish with us

Policies and ethics

Search

Navigation